Seroprevalence of Anti-bodies Against Clostridium Difficile Toxins and Prevalence of Asymptomatic Carriage of Clostridium Difficile in IBD Patients.

Seroprevalence of Anti-bodies Against Clostridium Difficile Toxins and Prevalence of Asymptomatic Carriage of Clostridium Difficile in IBD Patients.

The objective of this study to evaluate the seroprevalence of anti-bodies against C. difficile toxins A and B and the asymptomatic carriage of C. difficile in IBD patients according to the need and type of immunosuppressive therapy. The ultimate goal is to identify, among IBD patients, those with the highest risk of CDI.

Inclusion Criteria:

• Signed informed consent
• Diagnosed of IBD, either Crohn's disease or ulcerative colitis
• Age: >18 and <65 years
• Time since diagnoses of IBD ≥ 6 months
• Present with the criteria included in any of the 4 specified groups in the study population

Exclusion Criteria:

• History of documented CDI
• Active CDI at the moment of study inclusion
• Any of the following immunosuppressive conditions: HIV infection, Liver cirrhosis, CKD stage IV, Receiving chemotherapy, Transplant (solid organ or hematological), Concomitant neoplasia, Hypogammaglobinemia.